Crossmark

Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease

Crossref DOI link: https://doi.org/10.1186/s12885-020-06963-6

Published Online: 2020-05-24

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Thiis-Evensen, Espen https://orcid.org/0000-0003-0029-6481
Poole, Amalie Christine

Nguyen, Hong-Thien Thi

Sponheim, Jon
License Information

Text and Data Mining valid from 2020-05-24

Version of Record valid from 2020-05-24
More Information

Article History

Received: 25 February 2020

Accepted: 14 May 2020

First Online: 24 May 2020

Ethics approval and consent to participate

: The institutional review board approved the study and approved accessing the medical files of the participating patients (Personvernombudet, Oslo University Hospital, executive officer Anika Mortensen). As this study was an observational study with no intervention, informed consent from the patients was not necessary according to the national standard (Norwegian Health Record Act §6–2, and The Health Personnel Act).

: Not applicable.

: Espen Thiis-Evensen has received an unrestricted research grants from Novartis and has also received speaker honorarium from Novartis, Ipsen, Pfizer and MSD. Jon Sponheim has received a received speaker honorarium from Ipsen.Amalie Christine Poole, Hong-Thien Thi Nguyen have no conflicts of interest to declare.

Document is current

Any future updates will be listed below